Table 1 Characteristics of the study population Group 1 (healthy controls), group 2 (untreated asthmatic patients) and group 3 (asthmatic patients receiving inhaled glucocorticoid therapy)
From: Alveolar nitric oxide and its role in pediatric asthma control assessment
Group 1 (N = 49) | Group 2 (N = 23) | Group 3 (N = 80) | p | |
|---|---|---|---|---|
Age (years) (mean ± SD) | 10.1 ± 1.9 | 9.3 ± 2.06 | 10.7 ± 2.85 | NS |
Sex F/M | 28/21 | 10/13 | 29/51 | NS |
Weight (kg) (mean ± SD) | 38 ± 13.9 | 36 ± 10.3 | 42.1 ± 15.2 | NS |
Height (cm) (mean ± SD) | 139.4 ± 13.2 | 137.7 ± 11.5 | 144.84 ± 16.2 | NS |
Atopic dermatitis N (%) | 0 | 8 (34.7) | 30 (37.5) | |
Allergic rhinitis N (%) | 0 | 19 (82.6) | 70 (87.5) | |
Food allergy N (%) | 0 | 0 | 12 (15) | |
Mild asthma N (%) | 0 | 19 (82.6) | 57 (71.2) | |
Moderate asthma N (%) | 0 | 4 (17.4) | 23 (28.7) | NS |
Degree of control N (%) | ||||
- Good | 0 | 15 (65.2) | 63 (78.7) | NS |
- Partial | 0 | 6 (26) | 11 (13.7) | |
- Poor | 0 | 2 (8.7) | 6 (7.5) | |
ICS dose (fluticasone mcg) (mean ± SD) | 0 | 0 | 135.45 (35.2) | |
CAN (median and range) | 0 | 5 (0–29) | 5 (0–27) | NS |
FEV 1 (mean ± SD) | 0 | 98.17 (15.07) | 99.65 (10.59) | NS |
FE NO,50 (ppb) (median and range) | 11.5 (1.6-27.3) | 48.3 (7.4-122) | 32 (3.5-234) | p = 0.002 (2 vs 3) p < 0.001 (1 vs 2 and 3) |
J’aw NO (pl/s) (median and range) | 516 (98.3-1470) | 2356.7 (120–6110) | 1426 (156–11805) | p = 0.001 (2 vs 3) p < 0.001 (1 vs 2 and 3) |
CA NO (ppb) (median and range) | 2.2 (0.1-4.5) | 3.0 (0.2-9.2) | 2.4 (0.1-24) | NS ( 2 vs 3) P = 0.022 (1 vs 2 and 3) |